On the other hand, anti-TNF therapy is able to decrease the proportion of peripheral Th1, Th17 and IFN-γ-producing CD8+ T cells in RA patients [33], with simultaneous increase in the percentages of Tregs and, remarkably, in IFN-γ-producing NK cells. Here, CD8A is linked to rheumatoid arthritis.